XTX Topco Ltd Buys Shares of 4,578 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

XTX Topco Ltd purchased a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 4,578 shares of the biotechnology company’s stock, valued at approximately $723,000.

Other large investors also recently modified their holdings of the company. Principal Securities Inc. acquired a new position in Sarepta Therapeutics in the 4th quarter worth about $26,000. Mather Group LLC. bought a new stake in shares of Sarepta Therapeutics during the first quarter worth about $28,000. Riggs Asset Managment Co. Inc. increased its stake in shares of Sarepta Therapeutics by 125.0% in the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 125 shares during the period. Innealta Capital LLC bought a new position in Sarepta Therapeutics in the 2nd quarter valued at approximately $31,000. Finally, New Covenant Trust Company N.A. acquired a new stake in Sarepta Therapeutics during the 1st quarter worth approximately $32,000. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Stock Up 0.1 %

SRPT stock opened at $127.21 on Monday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 3.19 and a current ratio of 3.90. Sarepta Therapeutics, Inc. has a fifty-two week low of $55.25 and a fifty-two week high of $173.25. The stock’s 50 day simple moving average is $137.26 and its 200 day simple moving average is $132.75. The company has a market cap of $12.02 billion, a P/E ratio of 1,156.45 and a beta of 0.81.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. The company had revenue of $362.90 million for the quarter, compared to analysts’ expectations of $394.38 million. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. Sarepta Therapeutics’s quarterly revenue was up 38.9% compared to the same quarter last year. During the same period last year, the business earned ($0.27) EPS. On average, research analysts expect that Sarepta Therapeutics, Inc. will post 1.47 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on SRPT shares. Barclays dropped their price target on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. Leerink Partners lifted their target price on Sarepta Therapeutics from $165.00 to $230.00 and gave the stock an “outperform” rating in a report on Monday, June 24th. Morgan Stanley reissued an “overweight” rating and issued a $165.00 price target on shares of Sarepta Therapeutics in a research note on Friday, June 21st. Evercore ISI upgraded Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and reduced their target price for the company from $185.00 to $179.00 in a report on Thursday, August 8th. Finally, UBS Group raised their price target on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Three research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $187.39.

Insider Activity

In related news, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the sale, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, EVP Ryan Edward Brown sold 38,957 shares of the company’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $161.61, for a total value of $6,295,840.77. Following the completion of the sale, the executive vice president now owns 17,129 shares in the company, valued at approximately $2,768,217.69. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now directly owns 33,946 shares in the company, valued at $4,662,822.56. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.